Varian Medical Systems Inc

Varian Medical Systems — Q4 2017 Earnings Presentation

31 slides from Varian Medical Systems's earnings presentation, Oct 25, 2017

  1. Slide 1: Fourth Quarter Fiscal Year 2017

    Fourth Quarter Fiscal Year 2017 J. Michael Bruff Vice President Investor Relations [email protected] October 25, 2017

  2. Slide 2: Forward-Looking Statements

    FORWARD - LOOKING STATEMENTS Except for historical information, this presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Statements concerning industry outlook, including growth drivers, future trends in cancer incidence and

  3. Slide 3: Our fight against cancer

    Our fight against cancer Recognized global market leader in radiation therapy Radiation Oncology professionals ranked Varian first in eight major categories with a customer Net Promoter Score (NPS) of 75 Strengthening our leadership Launched Halcyon TM and HyperArc TM , high - quality and innovative

  4. Slide 4: Business Highlights FY 2017

    FY 2017 Business Highlights varian

  5. Slide 5: New branding and mission statement

    New branding and mission statement Our vision is a world without the fear of cancer. Our mission is to support and combine the ingenuity of people with the power of data and technology to achieve new victories against cancer. 5

  6. Slide 6: FY17 Year in review

    FY17 Year in review Varian Named Top Healthcare Equipment and Services Company on Inaugural “Just 100” List from JUST Capital and Forbes Varian Medical Systems Board of Directors Authorizes Repurchase of Additional 8 Million Shares of Stock José Baselga and Jean - Luc Butel Appointed to Board of Dir

  7. Slide 7: Financial Overview FY 2017

    Financial Overview EY 2017 varian

  8. Slide 8: Varian consolidated (GAAP) Key P&L Financial Metrics

    Varian consolidated (GAAP) Key P&L Financial Metrics VARIAN FISCAL 2017 FISCAL 2017 $M 4Q Y/Y Full Year Y/Y Gross Orders $1,039 11% $3,135 11% Revenues $739 - 1% $2,668 2% Product $442 - 7% $1,555 - 2% Svcs $297 9% $1,113 7% GM $311 - 2% $1,156 4% % of Rev 42.1% - 52 bps 43.3% 86 bps SG&A $150 20% $

  9. Slide 9: Varian consolidated (non-GAAP) Key P&L Financial Metrics

    Varian consolidated (non - GAAP) Key P&L Financial Metrics • Achieved $1B in gross orders in 4Q; double - digit orders growth for the year • Oncology orders mix: North America 48%, International 52% • 50 orders for Halcyon in the year, 40 orders for HyperArc • Grew Linac install base 4% in FY 2017 •

  10. Slide 10: Varian consolidated Key Balance Sheet and Cash Flow Metrics

    Varian consolidated Key Balance Sheet and Cash Flow Metrics • Accelerated cash flow from operations in the back half of fiscal 2017 • Strengthened financial flexibility by decreasing debt throughout the year VARIAN FISCAL 2017 $M 1Q 2Q 3Q 4Q Full Year Cash & Cash Equivalents 1 $815 $706 $658 $716 -

  11. Slide 11: Oncology business unit Key Financial Metrics

    Oncology business unit Key Financial Metrics • Strong finish to the year with orders growth at 7% • Product revenue decline driven by EMEA business primarily due to emerging market order mix increase over last 2 years • As install base grows, TrueBeam TM and Halcyon combined unit mix increases • Gro

  12. Slide 12: Oncology gross orders by geography (GAAP)

    Oncology gross orders by geography (GAAP) AMERICAS 1% 4Q Y/Y 3% FY Y/Y APAC 10% 4Q Y/Y 7% FY Y/Y EMEA 32% 4Q Y/Y 14% FY Y/Y 12

  13. Slide 13: Proton business unit Key Financial Metrics

    Proton business unit Key Financial Metrics • Strong orders growth; 6 new orders across 4 countries in the year • 5 clinically operational sites with 19 rooms in 3 countries; 16 more customers in varying stages of construction across the world • Revenue and margin volatility until we get to operation

  14. Slide 14: Proton orders by geography (GAAP)

    Proton orders by geography (GAAP) AMERICAS 83% 4Q Y/Y 1498% FY Y/Y APAC +75% 4Q Y/Y 12% FY Y/Y EMEA 185% 4Q Y/Y 22% FY Y/Y 14

  15. Slide 15: Long-Term Strategy & FY 2018 Guidance

    Long - Term Strategy & FY 2018 Guidance

  16. Slide 16: Global Leader in Radiation Therapy

    Global Leader Long - term growth and value creation strategy in Radiation Therapy Global Leader of multi - disciplinary, integrated cancer care solutions Radiosurgery systems Proton therapy Brachytherapy Radiotherapy Radiation oncology tracking software Medical oncology Radiation oncology Interventi

  17. Slide 17: Growth priorities and strategic enablers

    Growth priorities and strategic enablers We are here Long - Term Growth and Strategic Value Creation Strategy Global Leader in Radiation Therapy Growth Priorities Strategic Enablers Global Leader of Multi - Disciplinary, Integrated Cancer Care Solutions Strengthen Leadership in Radiation Therapy Ext

  18. Slide 18: Growth priority: Strengthen our leadership in radiation therapy

    Growth priority: Strengthen our leadership in radiation therapy 1 Source: Varian Press Release, September 2017 . Original Source: IMV, Ltd. Launched HyperArc our high - definition radiotherapy technology ⁃ 40 orders in the fourth quarter and treated its first patient in Negrar , Italy Market leader

  19. Slide 19: Growth priority: Extend global footprint

    Growth priority: Extend global footprint Proton Therapy business extended global footprint with Q4 wins at HCG in India the first in that country, and at Concord Medical Proton Center in China ⁃ 5 clinically operational sites with 19 rooms in 3 countries ⁃ 16 additional customers in varying stages o

  20. Slide 20: Growth priority: Expand addressable market

    Growth priority: Expand addressable market Software orders grew double - digits during Q4 and FY 2107; newer applications fueling enthusiasm ⁃ 360 Oncology cloud based, oncology - focused operating platform enables better, more informed decisions by the multidisciplinary teams engaged in a patient’s

  21. Slide 21: Varian consolidated FY18 Guidance

    Varian consolidated FY18 Guidance • Revenue and EPS guidance transitioning to full year guidance effective FY18 • However, adding annual guidance for non - GAAP operating Earnings as percent of revenue, effective tax rate, weighted average diluted share count and cash flow from operations (1) These

  22. Slide 22: Appendix

    Appendix

  23. Slide 23: Non-GAAP disclosure

    Non - GAAP disclosure 23 Discussion of Non - GAAP Financial Measures This presentation includes the following non - GAAP financial measures derived from our Condensed Consolidated Statements of Earnings : non - GAAP operating earnings, non - GAAP net earnings and non - GAAP net earnings per diluted

  24. Slide 24: GAAP to non-GAAP reconciliation

    GAAP to non - GAAP reconciliation 24 (1) Includes $1.3 million, $1.2 million, $1.2 million, $1.3 million and $5.0 million respectively, in cost of revenues for the pe rio ds presented. (2) Other includes acquisition - related expenses and benefits. (3) Excludes immaterial net earnings (loss) from co

  25. Slide 25: Total revenues by sales classification

    Total revenues by sales classification 25 $M 1Q 2Q 3Q 4Q FY17 Product revenues $343.6 $386.1 $383.4 $442.4 $1,555.5 Y/Y - 6% 7% 1% - 7% - 2% Service revenues $268.2 $268.9 $279.0 $296.6 $1,112.7 Y/Y 8% 6% 7% 9% 7% Total revenues $611.8 $655.0 $662.4 $739.0 $2,668.2 Y/Y - 1% 6% 3% - 1% 2% Y/Y – CC -

  26. Slide 26: Total revenues by region

    Total revenues by region 26 $M 1Q 2Q 3Q 4Q FY17 Americas revenues $306.0 $328.8 $352.5 $376.5 $1,363.8 Y/Y 4% 3% 16% 3% 6% Y/Y – CC 3% 2% 16% 3% 6% EMEA revenues $189.0 $186.1 $171.9 $224.6 $771.6 Y/Y - 17% 11% - 16% 0% - 6% Y/Y – CC - 14% 15% - 13% - 2% - 5% APAC revenues $116.8 $140.1 $138.0 $137.

  27. Slide 27: Total Oncology revenues by sales classification

    Total Oncology revenues by sales classification 27 $M 1Q 2Q 3Q 4Q FY17 Product revenues $316.8 $356.0 $316.9 $393.3 $1,383.0 Y/Y - 8% 7% - 8% - 4% - 3% Y/Y – CC - 8% 8% - 8% - 4% - 3% Service revenues $264.7 $267.7 $277.1 $293.2 $1,102.7 Y/Y 7% 6% 7% 8% 7% Y/Y – CC 7% 7% 8% 8% 7% Total revenues $581

  28. Slide 28: Total Oncology revenues by region

    Total Oncology revenues by region 28 $M 1Q 2Q 3Q 4Q FY17 Americas revenues $298.6 $319.2 $303.2 $355.0 $1,276.0 Y/Y 5% 4% 4% 2% 4% Y/Y – CC 5% 4% 3% 2% 4% EMEA revenues $174.0 $168.3 $160.0 $201.2 $703.5 Y/Y - 18% 11% - 11% 3% - 5% Y/Y – CC - 16% 15% - 8% 0% - 3% APAC revenues $108.9 $136.2 $130.8 $

  29. Slide 29: Total Proton revenues by sales classification

    Total Proton revenues by sales classification 29 $M 1Q 2Q 3Q 4Q FY17 Product revenues $26.8 $30.1 $66.5 $49.1 $172.5 Y/Y 10% 5% 91% - 25% 13% Service revenues $3.5 $1.2 $1.9 $3.4 $10.0 Y/Y 68% - 49% - 24% 26% 4% Total revenues $30.3 $31.3 $68.4 $52.5 $182.5 Y/Y 15% 1% 84% - 23% 12% VPT revenues as a

  30. Slide 30: Oncology gross orders by region

    Oncology gross orders by region 30 $M 1Q 2Q 3Q 4Q FY17 Americas orders $296.8 $342.2 $351.0 $489.0 $1,479.0 Y/Y 5% 3% 3% 1% 3% Y/Y – CC 5% 3% 3% 2% 3% EMEA orders $166.6 $184.8 $206.0 $320.8 $878.2 Y/Y 8% 6% 2% 32% 14% Y/Y – CC 10% 10% 5% 29% 14% APAC orders $122.7 $120.7 $150.7 $154.5 $548.6 Y/Y 29

  31. Slide 31: Fourth Quarter Fiscal Year 2017

    Fourth Quarter Fiscal Year 2017

Varian Medical Systems — Q4 2017 Earnings Presentation on 6ix